Do multiple outcome measures require p-value adjustment? by Feise, Ronald J
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Medical Research 
Methodology
BMC Medical Research Methodology  2002,  2 x Debate
Do multiple outcome measures require p-value adjustment?
Ronald J Feise
Address: Institute of Evidence-Based Chiropractic 6252 Rookery Road, Fort Collins, Colorado 80528
E-mail: rjf@chiroevidence.com
Abstract
Background: Readers may question the interpretation of findings in clinical trials when multiple
outcome measures are used without adjustment of the p-value. This question arises because of the
increased risk of Type I errors (findings of false "significance") when multiple simultaneous
hypotheses are tested at set p-values. The primary aim of this study was to estimate the need to
make appropriate p-value adjustments in clinical trials to compensate for a possible increased risk
in committing Type I errors when multiple outcome measures are used.
Discussion: The classicists believe that the chance of finding at least one test statistically significant
due to chance and incorrectly declaring a difference increases as the number of comparisons
increases. The rationalists have the following objections to that theory: 1) P-value adjustments are
calculated based on how many tests are to be considered, and that number has been defined
arbitrarily and variably; 2) P-value adjustments reduce the chance of making type I errors, but they
increase the chance of making type II errors or needing to increase the sample size.
Summary: Readers should balance a study's statistical significance with the magnitude of effect,
the quality of the study and with findings from other studies. Researchers facing multiple outcome
measures might want to either select a primary outcome measure or use a global assessment
measure, rather than adjusting the p-value.
Background
Clinical trials often require a number of outcomes to be
calculated and a number of hypotheses to be tested. Such
testing involves comparing treatments using multiple out-
come measures (MOMs) with univariate statistical meth-
ods. Studies with MOMs occur frequently within medical
research [1]. Some researchers recommend adjusting the
p-values when clinical trials use MOMs so as to prevent
the findings from falsely claiming "statistical significance"
[2]. Other researchers have disagreed with this strategy,
because it is inappropriate and may cause incorrect con-
clusions from the study [3]. The examination of this issue
is important to both researchers and readers. Researchers
are concerned about p-values and their effect upon power
and sample size. Both readers and researchers are con-
cerned about accepting erroneous studies and rejecting
beneficial interventions. The primary aim of this study
was to evaluate the need to adjust p-values in clinical trials
when MOMs are used.
Discussion
Classical view
Classicists believe that if multiple measures are tested in a
given study, the p-value should be adjusted upward to re-
duce the chance of incorrectly declaring a statistical signif-
icance [4–7]. This view is based on the theory that if you
test long enough, you will inevitably find something sta-
tistically significant – false-positives due to random varia-
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bility, even if no real effects exist [4–7]. This has been
called the multiple testing problem or the problem of
multiplicity [8].
Adjustments to p-value are founded on the following log-
ic: If a null hypothesis is true, a significant difference may
still be observed by chance. Rarely can you have absolute
proof as to which of the two hypotheses (null or alterna-
tive) is true, because you are only looking at a sample, not
the whole population. Thus, you must estimate the sam-
pling error. The chance to incorrectly declare an effect be-
cause of random error in the sample is called type I error.
Standard scientific practice, which is entirely arbitrary,
commonly establishes a cutoff point to distinguish statis-
tical significance from non-significance at 0.05. By defini-
tion, this means that one test in 20 will appear to be
significant when it is really coincidental. When more than
one test is used, the chance of finding at least one test sta-
tistically significant due to chance and incorrectly declar-
ing a difference increases. When 10 statistically
independent tests are performed, the chance of at least
one test being significant is no longer 0.05, but 0.40. To
accommodate for this, the p-value of each individual test
is adjusted upward to ensure that the overall risk or fami-
ly-wise error rate for all tests remains 0.05. Thus, even if
more than one test is done, the risk of finding a difference
incorrectly significant continues to be 0.05, or one in
twenty [4–7].
Those who advocate multiple comparison adjustments ar-
gue that the control for false-positives is imperative, and
any study that collects information on a large number of
outcomes has a high probability of producing a wild
goose chase and thereby consuming resources. Thus, the
main benefit of adjusting p-value is the weeding out of
false positives [4–7,9]. Although Bonferroni is the classi-
cal method of adjusting p-value, it is often considered to
be overly conservative. A variety of alternative methods
have been developed, but no gold standard method exists
[10–21].
Original intent
An examination of the need for p-value adjustments
should begin by asking why adjustments for MOMs were
developed in the first place. Neyman and Pearson's origi-
nal statistical test theory in the 1920s was a theory of mul-
tiple tests, and it was used to aid decisions in repetitive
industrial circumstances, not to appraise evidence in stud-
ies [22,23]. Neyman and Pearson were solving problems
surrounding rates of defective materials and rejection of
lots where there were multiple samples within each lot –
a situation which clearly does require a p-value adjust-
ment.
Rational analysis
The opponents of p-value adjustments raise several practi-
cal objections. One objection to p-value adjustments is
that the significance of each test will be interpreted ac-
cording to how many outcome measures are considered
in the family-wise hypothesis, which has been defined
ambiguously, arbitrarily and inconsistently by its advo-
cates. Hochberg and Tamhane define family-wise error
rate as any collection of inferences, including potential in-
ferences, for which it is meaningful to take into account
some combined measure of errors [17]. It is unclear how
wide the operative term "family" should be. Thus, the use
of a finite number of comparisons is problematic. Does
"family" include tests that were performed, but not pub-
lished? Does it include a meta-analysis upon those tests?
Should future papers on the same data set be accounted
for in the first publication? Should each researcher have a
career-wise adjusted p-value, or should there be a disci-
pline-wise adjusted p-value? Should we publish an issue-
wise adjusted p-value and a year-end-journal-wise adjust-
ed p-value? Should our studies examine only one associa-
tion at a time, thereby wasting valuable resources? No
statistical theory provides answers for these practical is-
sues, because it is impossible to formally account for an
infinite number of potential inferences [23–26].
An additional objection to p-value adjustments is that if
you reduce the chance of making a type I error, you in-
crease the chance of making a type II error [23,24,27,28].
Type II errors can be no less important than type I errors,
and by reducing for individual tests the chance of type I er-
rors (the chance of introducing ineffective treatments),
you increase the chance of type II errors (the chance that
effective treatments are not discovered). Thus, the conse-
quences of both Type I and Type II errors need to be con-
sidered, and the relation between them established on the
basis of their severity. Additionally, if you lower the alpha
level and maintain the beta level in the design phase of a
study, you will need to increase the sample size, thereby
increasing the financial burden of the study.
The debate over the need for p-value adjustments focuses
upon our ability to make distinctions between different
results – to judge the quality of science. Obviously, no sci-
entist wants coincidence to determine the efficacy of an
intervention. But MOMs have produced a tension be-
tween reason and the classical technology of statistical
testing [29,30]. The issue cannot be sidestepped by using
confidence intervals (which are preferred by most major
medical journals), because it applies equally to statistical
testing and confidence intervals. Moreover, the use of
multivariate tests in place of univariate tests does not
solve the dilemma, because multivariate tests present their
own shortfalls, including interpretation problems (if
there is a difference between experimental groups, multi-BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/8
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variate tests do not tell us which variable might differ as a
result of treatment, and univariate testing may still be
needed). Thus, we need to confront the uncomfortable
and subjective nature of the most critical scientific activity
– assessing the quality of our findings. Ideally, we should
be able to recognize the well-grounded and dismiss the
contrived. But we might have to admit that there is no one
correct or absolute way to do this.
Conscientious readers of research should consider wheth-
er a given study needs to be statistically analyzed at all. We
must be careful to focus not only upon statistical signifi-
cance (adjusted or not), but also upon the quality of the
research within the study and the magnitude of improve-
ment. Effect size and the quality of the research are as im-
portant as significance testing! Does it really matter
whether there is a statistical difference between two treat-
ments if the difference is not clinically worthwhile or if
the research is marred by bias?
An astute reader of research knows that statistical signifi-
cance is a statistical statement of how likely or unlikely it
is that an outcome has occurred by chance. If a p-value is
.05, there is a rather large chance (1/20) that the finding is
in doubt. However, if a p-value is .0001, the chance of er-
ror is significantly less (1/10000).
Multiple comparisons strategies
To date, the issues that separate these two statistical camps
remain unresolved. Moreover, other strategies may be
used in lieu of p-value adjustment. Some authors have
suggested the use of a composite endpoint or global as-
sessment measure consisting of a combination of end-
points [31–34]. For example, in chronic fatigue syndrome
there are multiple manifestations that tend to affect differ-
ent people differently. Because no manifestation domi-
nates, there is no way to select a primary endpoint. Use of
a composite endpoint provides efficacy of "nonspecific"
benefits and is valuable in testing multiple endpoints that
are suitable for combining.
Zhang has advocated the selection of a primary endpoint
and several secondary endpoints as a possible method to
maintain the overall type I error rate [34]. For example, in
chronic low back pain, although there are numerous
measurements that can be used, a researcher might focus
the study on symptoms while using a pain instrument as
the key outcome and other measures (such as function,
cost, patient satisfaction, etc.) as secondary outcomes.
Even though selecting a single endpoint is not always easy
because of the multifarious sphere of conditions, it is a
practical approach. The selection of a primary outcome
measure or composite endpoint is also necessary in the
planning stages of any experimental trial to estimate the
study's power and sample size. Additionally, ethical re-
view boards, funding agencies and journals need a ration-
ale for handling the statistical conundrum of MOMs. The
selection of a primary outcome measure or a composite
endpoint provides such a rationale.
Reader strategies
The following strategies should enable the reader to reach
a reasonable conclusion, regardless of p-value adjust-
ments [23,25,27,28,35–39]:
1. Evaluate the quality of the of the study and the ampli-
tude (effect size) of the finding before interpreting statis-
tical significance.
2. Regard all findings as tentative until they are corrobo-
rated. A single study is most often not conclusive, no mat-
ter how statistically significant its findings. Each test
should be considered in the context of all the data before
reaching conclusions, and perhaps the only place where
"significance" should be declared is in systematic reviews.
Beware of serendipitous findings of fishing expeditions or
biologically implausible theories.
Author strategies
The following strategies are for the consideration of the
author-researcher when faced with MOMs [31–34]:
1. Select a primary endpoint or global assessment meas-
ure, as appropriate.
2. Communicate to your readers the roles of both Type I
and Type II errors and their potential consequences.
Summary
Statistical analysis is an important tool in clinical re-
search. Disagreements over the use of various approaches
should not cause us to waver from our aim to produce val-
id and reliable research findings. There are no "royal"
roads to good research [40], because in science we are nev-
er absolutely sure of anything.
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